capital · May 15, 2026
Isomorphic Labs' $2.1 Billion Raise Highlights AI Drug Discovery Momentum
Share the canonical public link.
Isomorphic Labs announced a $2.1 billion Series B funding round on May 13, 2026, led by Thrive Capital. Investors include Alphabet, GV, MGX from Abu Dhabi, Temasek from Singapore, CapitalG, and the UK Sovereign AI Fund. The capital accelerates IsoDDE engine scaling for therapeutic applications and global operations growth. Existing deals with Novartis, Eli Lilly, and Johnson & Johnson provide $600 million in near-term milestones based on development benchmarks. The firm, founded by Demis Hassabis in 2021, has raised $2.7 billion total without corporate venture involvement in this round.
Failed after 3 attempts. Last error: Service unavailable